The role of beliefs in the supply of health screenings

How to cite

Angerer, Silvia. 2024. "The role of beliefs in the supply of health screenings." AEA RCT Registry. AEARCTR-0013729. https://doi.org/10.1257/rct.13729-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Silvia Angerer*

* Primary investigator

Registry ID
AEARCTR-0013729
DOI
https://doi.org/10.1257/rct.13729-1.0
First registered
Last updated
Status
In development
Trial dates
2024-06-24 – 2024-08-05
Countries
Private
JEL codes
D80, D90, I10, I18
Registry record
http://www.socialscienceregistry.org/trials/13729

Abstract

Universal screening programs, where the entire population is invited for diagnostic tests, should have a favorable benefit-harm ratio and undergo continuous evaluation (WHO, 2020).
Despite promoting early detection as life-saving, evidence regarding cancer screening is mixed. A meta-analysis found that only colorectal cancer screening significantly increased life expectancy, while mammography and PSA tests did not (Bretthauer et al., 2023). Significant advances in breast cancer treatment and the unclear benefit-harm ratio of screenings call for re-evaluation of this program (Bretthauer et al., 2023; Saquib et al., 2015; Voss et al., 2023).
Austria offers free mammograms every two years for women aged 45-74, following European guidelines (Loibl et al., 2023). Clinical guidelines for prostate cancer have changed, and the PSA test for early detection is no longer recommended (Parker et al., 2020).
This project will investigate general practitioners' expectations and recommendations regarding breast cancer mammography and prostate cancer PSA tests, exploring their awareness of the actual benefits and how this influences their adherence to guidelines using a survey experiment with randomized information provision.

References

Bretthauer, M., Wieszczy, P., Løberg, M., Kaminski, M. F., Werner, T. F., Helsingen, L. M., Mori, Y., Holme, Ø., Adami, H.-O., & Kalager, M. 2023. Estimated Lifetime Gained With Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials. JAMA Internal Medicine, 183(11): 1196-1203.
Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, L. M. J., Carey, L. A., Dawood, S., Del Mastro, L., Denkert, C., Fallenberg, E. M., Francis, P. A., Gamal-Eldin, H., Gelmon, K., Geyer, C. E., Gnant, M., Guarneri, V., Gupta, S., Kim, S. B., Krug, D., Martin, M., Meattini, I., Morrow, M., Janni, W., Paluch-Shimon, S., Partridge, A., Poortmans, P., Pusztai, L., Regan, M. M., Sparano, J., Spanic, T., Swain, S., Tjulandin, S., Toi, M., Trapani, D., Tutt, A., Xu, B., Curigliano, G., & Harbeck, N. 2023. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>&#x2020;</sup>. Annals of Oncology.
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. 2020. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>&#x2020;</sup>. Annals of Oncology, 31(9): 1119-1134.
Saquib, N., Saquib, J., & Ioannidis, J. P. A. 2015. Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials. International journal of epidemiology, 44(1): 264-277.
Voss, T., Krag, M., Martiny, F., Heleno, B., Jørgensen, K. J., & Brandt Brodersen, J. 2023. Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews. Cancer Epidemiology, 84: 102352.
WHO. 2020. Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm (2020). Copenhagen: WHO Regional Office for Europe.

Experimental design

Survey experiment comprises random assignment of General Practitioners (GPs) to one of four experimental groups: (i) No information, (ii) Information about Guidelines regarding PSA and Mammography in Austria, (iii) Information about Guidelines and uncertainty regarding Benefit-Harm Ratio Mammography, (iv) Information about Guidelines, uncertainty regarding Benefit-Harm Ratio Mammography and evidence on all-cause-mortality.

Design details

Randomization method
Randomization done by the computer program used for the survey.
Randomization unit
Individual randomization to one of four experimental groups.
Clusters
400 GPs
Observations
400 GPs
Arms
100 GPs per experimental group
Primary outcomes
Recommendation for PSA-Test (self-reported) Recommendation for Mammography (self-reported)
Secondary outcomes
Beliefs about PSA/Mammography for (i) positive benefit-harm ratio and (ii) reduction in all-cause mortality Attitudes towards PSA and Mammography screening

Cited by

No citation data available for this registration yet.

Keywords